Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885117 | 0.82 | MAPT (0.49) | SORDKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL25489960 | 0.76 | SORD (0.44) | SORDKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3145713 | 0.72 | SORD (0.48) | SORDKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL2881173 | 0.67 | SCN9A (0.44) | HRH3 | |
| SCHEMBL3680699 | 0.66 | — | — | |
| SCHEMBL1876393 | 0.66 | KDM4E (0.43) | KDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL5596781 | 0.65 | SORD (0.43) | SORDKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL2320496 | 0.65 | SORD (0.51) | SORDKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL31014265 | 0.65 | SORD (0.51) | SORDKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL18228513 | 0.65 | SORD (0.51) | SORDKDM4EALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | claimed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | claimed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-7776854-B2 | Benzazole derivatives for the treatment of scleroderma | MERCK SERONO SA (CH) | 2010-08-17 | — | — | US | disclosed |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | disclosed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | disclosed |
| US-20050119277-A1 | Benzazole derivatives for the treatment of scleroderma | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-06-02 | — | — | US | disclosed |
| EP-1240164-B1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | MAP3K20, MAPK3, MAPK10 | SORD 3621/4885KDM4E 4094/4885ALDH1A1 4458/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | SORD 3875/4885KDM4E 3514/4885ALDH1A1 4785/4885 |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | MAPKAPK2, MAP3K20, MAP3K6 | SORD 2623/4885KDM4E 851/4885ALDH1A1 3262/4885 |
| US-20050119277-A1 | Benzazole derivatives for the treatment of scleroderma | SMAD3, SQOR, TNNI3 | SORD 606/4885KDM4E 2705/4885ALDH1A1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.